Sign In
Buy USPH
US Physical Therapy Earnings Calls
| Release date | May 06, 2026 |
| EPS estimate | $0.550 |
| EPS actual | $0.460 |
| EPS Surprise | -16.36% |
| Revenue estimate | 200.941M |
| Revenue actual | 198.286M |
| Revenue Surprise | -1.32% |
| Release date | Feb 25, 2026 |
| EPS estimate | $0.670 |
| EPS actual | $0.670 |
| Revenue estimate | 199.895M |
| Revenue actual | 202.726M |
| Revenue Surprise | 1.42% |
| Release date | Nov 05, 2025 |
| EPS estimate | $0.670 |
| EPS actual | $0.660 |
| EPS Surprise | -1.49% |
| Revenue estimate | 200.099M |
| Revenue actual | 164.024M |
| Revenue Surprise | -18.03% |
| Release date | Aug 06, 2025 |
| EPS estimate | $0.710 |
| EPS actual | $0.81 |
| EPS Surprise | 14.08% |
| Revenue estimate | 189.851M |
| Revenue actual | 164.183M |
| Revenue Surprise | -13.52% |
Last 4 Quarters for US Physical Therapy
Below you can see how USPH performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 06, 2025 |
| Price on release | $72.69 |
| EPS estimate | $0.710 |
| EPS actual | $0.81 |
| EPS surprise | 14.08% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $73.15 |
| Aug 01, 2025 | $69.98 |
| Aug 04, 2025 | $70.36 |
| Aug 05, 2025 | $72.02 |
| Aug 06, 2025 | $72.69 |
| Aug 07, 2025 | $83.75 |
| Aug 08, 2025 | $87.68 |
| Aug 11, 2025 | $86.71 |
| Aug 12, 2025 | $87.49 |
| 4 days before | -0.629% |
| 4 days after | 20.36% |
| On release day | 15.22% |
| Change in period | 19.60% |
| Release date | Nov 05, 2025 |
| Price on release | $88.05 |
| EPS estimate | $0.670 |
| EPS actual | $0.660 |
| EPS surprise | -1.49% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $86.22 |
| Oct 31, 2025 | $86.27 |
| Nov 03, 2025 | $86.93 |
| Nov 04, 2025 | $87.04 |
| Nov 05, 2025 | $88.05 |
| Nov 06, 2025 | $77.56 |
| Nov 07, 2025 | $73.87 |
| Nov 10, 2025 | $73.31 |
| Nov 11, 2025 | $74.39 |
| 4 days before | 2.12% |
| 4 days after | -15.51% |
| On release day | -11.91% |
| Change in period | -13.72% |
| Release date | Feb 25, 2026 |
| Price on release | $81.68 |
| EPS estimate | $0.670 |
| EPS actual | $0.670 |
| Date | Price |
|---|---|
| Feb 19, 2026 | $86.45 |
| Feb 20, 2026 | $85.09 |
| Feb 23, 2026 | $83.55 |
| Feb 24, 2026 | $82.88 |
| Feb 25, 2026 | $81.68 |
| Feb 26, 2026 | $79.34 |
| Feb 27, 2026 | $82.96 |
| Mar 02, 2026 | $83.03 |
| Mar 03, 2026 | $83.25 |
| 4 days before | -5.52% |
| 4 days after | 1.92% |
| On release day | -2.86% |
| Change in period | -3.70% |
| Release date | May 06, 2026 |
| Price on release | $73.61 |
| EPS estimate | $0.550 |
| EPS actual | $0.460 |
| EPS surprise | -16.36% |
| Date | Price |
|---|---|
| Apr 30, 2026 | $71.22 |
| May 01, 2026 | $71.83 |
| May 04, 2026 | $70.92 |
| May 05, 2026 | $71.74 |
| May 06, 2026 | $73.61 |
| May 07, 2026 | $59.00 |
| May 08, 2026 | $59.29 |
| May 11, 2026 | $59.42 |
| May 12, 2026 | $60.85 |
| 4 days before | 3.36% |
| 4 days after | -17.33% |
| On release day | -19.85% |
| Change in period | -14.56% |
US Physical Therapy Earnings Call Transcript Summary of Q1 2026
U.S. Physical Therapy reported Q1 2026 revenue growth driven by volume gains and reinforced its full-year guidance. Key operational initiatives include semi-virtual front desk, AI-assisted documentation, reengagement with remote therapeutic monitoring for traditional Medicare, expansion of cash-based programs (e.g., lasers, shockwave, dry needling), and pursuit of large hospital/system partnerships (NYU transition started). Q1 highlights: total revenue $198M (+7.9% y/y), physical therapy revenue $168M (+7.2%), total visits 1.543M (+6.9%), daily visits per clinic 31.8, net revenue per visit $106.49, adjusted EBITDA $20.2M for Q1 (+$0.7M y/y). IIP (industrial injury prevention) revenue grew 11.8% and margin expanded. Adjusted PT margin compressed modestly (16.1% vs. 16.8% prior year) due to weather-related visit losses (~31,000 visits, ≈$3.3M revenue impact), some mix effects (small Medicaid rate decline), and investments in initiatives. The company completed two acquisitions in Q1 and repurchased $14M of noncontrolling interests. It secured an upsized $450M five-year credit facility with improved pricing to support growth and M&A. Management reiterated full-year adjusted EBITDA guidance of $102M–$106M and expects hospital affiliations and technology/efficiency initiatives to ramp benefits through the year (hospital contribution to be phased in, more material by Q4).
